SooHoo Jeffrey R, Seibold Leonard K, Radcliffe Nathan M, Kahook Malik Y
Department of Ophthalmology, University of Colorado School of Medicine, Aurora, Colo.
Department of Ophthalmology, NYU School of Medicine, New York, N.Y.
Can J Ophthalmol. 2014 Dec;49(6):528-33. doi: 10.1016/j.jcjo.2014.09.002.
Traditionally, invasive surgical management of glaucoma is recommended when medication and/or laser trabeculoplasty fail to control intraocular pressure (IOP). Filtering procedures, such as trabeculectomy and glaucoma drainage devices, are effective in lowering IOP, but they have significant associated adverse events and rates of failure. For these reasons, a new group of surgical procedures has emerged that seeks to decrease IOP with lower associated rates of complications. The acronym MIGS, usually described as minimally invasive glaucoma surgery, has been coined to describe this group of procedures. As new devices become available, MIGS procedures will help to fill the gap between conservative medical and laser therapy and invasive surgical treatment of glaucoma to offer patients an earlier and safer transition to surgical management of their disease. In this review, we define the characteristics of an ideal MIGS procedure and discuss implants currently in use or under investigation.
传统上，当药物治疗和/或激光小梁成形术无法控制眼压（IOP）时，建议采用侵入性青光眼手术治疗。小梁切除术和青光眼引流装置等滤过手术在降低眼压方面是有效的，但它们伴有显著的不良事件和失败率。由于这些原因，出现了一组新的手术方法，旨在降低眼压并减少相关并发症的发生率。首字母缩写词MIGS，通常被描述为微创青光眼手术，已被用来描述这组手术方法。随着新设备的出现，MIGS手术将有助于填补青光眼保守药物和激光治疗与侵入性手术治疗之间的空白，为患者提供更早、更安全的疾病手术治疗过渡。在本综述中，我们定义了理想MIGS手术的特征，并讨论了目前正在使用或正在研究的植入物。
